iBio, Inc. (IBIO) income statement
IBIONasdaqPharmaceutical PreparationsFiscal year ends June 30
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/30
$0.85+0.10 (+13.37%)
Close on Nov 18, 2026Market cap $54.54MP/E –Yield –
iBio, Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -3491.0%
- Net margin
- -3244.2%
- Return on equity, FY2026
- -65.7%
Financial strength
- Current ratio
- 9.48
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 529.9%
Valuation
- P/E ratio
- –
- Price to sales
- 50.73
- Price to book
- 0.69
- Dividend yield
- –
See a number that looks wrong?